Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

Yasutomo Nakai; Ario Takeuchi; Takahiro Osawa; Takahiro Kojima; Tomohiko Hara; Mikio Sugimoto; Masatoshi Eto; Keita Minami; Kosuke Ueda; Michinobu Ozawa; Motohide Uemura; Yasuyuki Miyauchi; Kojiro Ohba; Akira Kashiwagi; Masaya Murakami; Tomokazu Sazuka; Hiroaki Yasumoto; Shuichi Morizane; Yoshihide Kawasaki; Daichi Morooka; Toru Shimazui; Yoshiaki Yamamoto; Hiroshi Nakagomi; Ryotaro Tomida; Yoichi M Ito; Sachiyo Murai; Hiroshi Kitamura; Hiroyuki Nishiyama; Nobuo Shinohara; Japanese Urological Oncology Group

doi:10.1016/j.jgo.2020.12.012

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

J Geriatr Oncol. 2021 Jun;12(5):834-837. doi: 10.1016/j.jgo.2020.12.012. Epub 2020 Dec 31.

Authors

Yasutomo Nakai¹, Ario Takeuchi², Takahiro Osawa³, Takahiro Kojima⁴, Tomohiko Hara⁵, Mikio Sugimoto⁶, Masatoshi Eto⁷, Keita Minami⁸, Kosuke Ueda⁹, Michinobu Ozawa¹⁰, Motohide Uemura¹¹, Yasuyuki Miyauchi⁶, Kojiro Ohba¹², Akira Kashiwagi¹³, Masaya Murakami¹⁴, Tomokazu Sazuka¹⁵, Hiroaki Yasumoto¹⁶, Shuichi Morizane¹⁷, Yoshihide Kawasaki¹⁸, Daichi Morooka¹⁹, Toru Shimazui²⁰, Yoshiaki Yamamoto²¹, Hiroshi Nakagomi²², Ryotaro Tomida²³, Yoichi M Ito²⁴, Sachiyo Murai²⁵, Hiroshi Kitamura²⁶, Hiroyuki Nishiyama⁴, Nobuo Shinohara²⁵; Japanese Urological Oncology Group

Affiliations

¹ Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
² Department of Urology, Kyushu University Hospital, Fukuoka, Japan.
³ Department of Urology, Hokkaido University Hospital, Sapporo, Japan. Electronic address: taka0573@gmail.com.
⁴ Department of Urology, University of Tsukuba Hospital, Tsukuba, Japan.
⁵ Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
⁶ Department of Urology, Kagawa University, Takamatsu, Japan.
⁷ Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
⁸ Department of Urology, Sapporo City General Hospital, Sapporo, Japan.
⁹ Department of Urology, Kurume University Hospital, Kurume, Japan.
¹⁰ Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan.
¹¹ Department of Urology, Osaka University Hospital, Suita, Japan.
¹² Department of Urology, Nagasaki University Hospital, Nagasaki, Japan.
¹³ Department of Urology, Teine Keijinkai Hospital, Sapporo, Japan.
¹⁴ Department of Urology, The Jikei University, School of Medicine, Tokyo, Japan.
¹⁵ Department of Urology, Chiba University, Chiba, Japan.
¹⁶ Department of Urology, Shimane University, Izumo, Japan.
¹⁷ Department of Urology, Tottori University, Yonago, Japan.
¹⁸ Department of Urology, Tohoku University, Sendai, Japan.
¹⁹ Department of Urology, Hakodate Goryoukaku Hospital, Hakodate, Japan.
²⁰ Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan.
²¹ Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
²² Department of Urology, University of Yamanashi Hospital, Chuo, Japan.
²³ Department of Urology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
²⁴ Biostatistics Division, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
²⁵ Department of Urology, Hokkaido University Hospital, Sapporo, Japan.
²⁶ Department of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.

PMID: 33388281
DOI: 10.1016/j.jgo.2020.12.012

No abstract available

Keywords: Metastatic; Octogenarians; Renal cell carcinoma; Systemic therapy.

Publication types

Letter

MeSH terms

Aged, 80 and over
Antineoplastic Agents* / adverse effects
Axitinib / adverse effects
Carcinoma, Renal Cell* / drug therapy
Humans
Indazoles / adverse effects
Kidney Neoplasms* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Treatment Outcome

Substances

Antineoplastic Agents
Indazoles
Protein Kinase Inhibitors
Axitinib